U.S. Jobless Claims: Another good metric but…

U.S. Jobless Claims: Another good metric but…

Macro
CD
Christopher Dembik

Head of Macro Analysis

Summary:  U.S. initial jobless claims and continuing claims are down again - which is rather positive considering the reintroduction of new business restrictions in states due to rising Covid-19 counts. However, the market is not really impressed. (1) Continuing claims remain still very elevated, at 5.500k versus 1,700k before the outbreak. (2) Investors are all eyeing at tomorrow's government jobs report to have a better picture of the real state of the labor market.


Today’s U.S. labor market statistics are better-than-expected but the market impact is rather limited. Initial jobless claims, which does not capture the rate of hiring and rehiring, declined from 778k to 712k last week (Nov. 28). This is the first time since the outbreak that initial claims are reaching such a low level (versus 282k pre-Covid). Continuing claims, which represent the current number of insured unemployed workers filing weekly for unemployment insurance benefits, are reported with a two-week lag. In the week ending Nov. 22, it was standing at 5,520k vs 6,089k the prior week. Before Covid, continuing claims were at 1,702k, which is three times lower than the current level. It shows the extend of the crisis on the labor market and it highlights there is still a long way to go before getting back to the pre-pandemic era. Looking at states level, we observe a slight deterioration in the labor market in Illinois (initial jobless claims at +18.8k), Michigan (+17.3k) and Washington (+13.5k). At the other end of the spectrum, the greatest decreases in initial jobless claims occurred in Louisiana (-33.6k), Massachusetts (-22.6k) and New Jersey (-783). So far, the new business restrictions that have been implemented in various states over the month of November do not seem to have derailed the recovery in the labor market. But the worst might be to come. The risk is elevated that the United States will face a post-Thanksgiving covid surge that might be amplified by the upcoming Christmas holiday. Although the vaccination campaign might start at the end of the month in the United States, after the FDA will deliver emerging authorization use for the Pfizer vaccine (around Dec. 10), it is not excluded that new restrictions will be put in place in the short term if the number of cases continues to increase, which would seriously disrupt the recovery of the labor market in the United States. Said differently, there is no cause for happiness in today’s data.

Disclaimer

Saxo Capital Markets (Australia) Limited prepares and distributes information/research produced within the Saxo Bank Group for informational purposes only. In addition to the disclaimer below, if any general advice is provided, such advice does not take into account your individual objectives, financial situation or needs. You should consider the appropriateness of trading any financial instrument as trading can result in losses that exceed your initial investment. Please refer to our Analysis Disclaimer, and our Financial Services Guide and Product Disclosure Statement. All legal documentation and disclaimers can be found at https://www.home.saxo/en-au/legal/.

The Saxo Bank Group entities each provide execution-only service. Access and use of Saxo News & Research and any Saxo Bank Group website are subject to (i) the Terms of Use; (ii) the full Disclaimer; and (iii) the Risk Warning in addition (where relevant) to the terms governing the use of the website of a member of the Saxo Bank Group.

Saxo News & Research is provided for informational purposes, does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. No Saxo Bank Group entity shall be liable for any losses that you may sustain as a result of any investment decision made in reliance on information on Saxo News & Research.

To the extent that any content is construed as investment research, such content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication.

None of the information contained here constitutes an offer to purchase or sell a financial instrument, or to make any investments.Saxo Capital Markets does not take into account your personal investment objectives or financial situation and makes no representation and assumes no liability as to the accuracy or completeness of the information nor for any loss arising from any investment made in reliance of this presentation. Any opinions made are subject to change and may be personal to the author. These may not necessarily reflect the opinion of Saxo Capital Markets or its affiliates.

Please read our disclaimers:
- Full Disclaimer (https://www.home.saxo/en-au/legal/disclaimer/saxo-disclaimer)
- Analysis Disclaimer (https://www.home.saxo/en-au/legal/analysis-disclaimer/saxo-analysis-disclaimer)
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)

Saxo Capital Markets (Australia) Limited
Suite 1, Level 14, 9 Castlereagh St
Sydney NSW 2000
Australia

Contact Saxo

Select region

Australia
Australia

The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit www.home.saxo/en-au/about-us/awards

Saxo Capital Markets (Australia) Limited ABN 32 110 128 286 AFSL 280372 (‘Saxo’ or ‘Saxo Capital Markets’) is a wholly owned subsidiary of Saxo Bank A/S, headquartered in Denmark. Please refer to our General Business Terms, Financial Services Guide, Product Disclosure Statement and Target Market Determination to consider whether acquiring or continuing to hold financial products is suitable for you, prior to opening an account and investing in a financial product.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Saxo Capital Markets does not provide ‘personal’ financial product advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo Capital Markets does not take into account an individual’s needs, objectives or financial situation. The Target Market Determination should assist you in determining whether any of the products or services we offer are likely to be consistent with your objectives, financial situation and needs.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc.

The information or the products and services referred to on this website may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and Services offered on this website is not intended for residents of the United States and Japan.

Please click here to view our full disclaimer.